Nexia gets encouraging news on Protexia from U.S. Army
2003-11-20 11:38 ET - News Release
Mr. Jeffrey Turner reports
THE U.S. ARMY AND NEXIA ANNOUNCE PROTEXIA(TM) RESULTS
Nexia Biotechnologies client, the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD), presented results from its Protexia program at the Joint Services Scientific Conference on Chemical and Biological Defense in Towson, Md.
The results indicate that Protexia, manufactured in transgenic goats, binds a broad spectrum of nerve agents and has properties very similar to human butyrylcholinesterase (HuBChE) when compared in vitro under identical conditions. The data also indicate that Protexia is capable of binding stoichiometrically with nerve agents on a one-molecule-to-one-molecule basis.
Protexia program update
Nexia is developing a recombinant version of human butyrylcholinesterase (Protexia), a bioscavenger, as a medical countermeasure for nerve agents. Nexia continues to collaborate with both the USAMRICD and Defence R&D Canada Suffield (DRDC Suffield) to test Protexia in both in vitro and in vivo model systems. Three key milestones have been targeted within the next 12 months:
first, to demonstrate in vitro binding and neutralization by Protexia of a variety of nerve agents, including soman, sarin, VX and tabun. Today's disclosure by the U.S. Army of the results of these experiments marks the successful completion of this first milestone;
second, conduct early preclinical tests, including pharmacokinetic studies, to determine residence time of Protexia in animal models; and
News 
Market Data 
Discover 
